### Highlights of This Issue 4171

#### SPECIAL FEATURES

### CCR Translations

**4173** CHK It Out! Blocking WEE Kinase Routs TP53 Mutant Cancer  
Julie E. Bauman and Christine H. Chung  
*See related article, p. 4274*

### Statistics in Clinical Cancer Research

**4176** Historical Controls for Metastatic Pancreatic Cancer: Benchmarks for Planning and Analyzing Single-Arm Phase II Trials  
Philip A. Philip, Kari Chansky, Michael LeBlanc, Lawrence Rubinstein, Lesley Seymour, S. Percy Ivy, Steven R. Alberts, Paul J. Catalano, and John Crowley

### Molecular Pathways

**4186** Molecular Pathways: Targeting NRAS in Melanoma and Acute Myelogenous Leukemia  
Douglas B. Johnson, Keiran S.M. Smalley, and Jeffrey A. Sosman

**4193** Molecular Pathways: The Basis for Rational Combination Using MEK Inhibitors in KRAS-Mutant Cancers  
Shunsuke Okumura and Pasi A. Jänne

### Perspectives

**4200** Toward a Drug Development Path That Targets Metastatic Progression in Osteosarcoma  

### CANCER THERAPY: CLINICAL

**4210** Design of Phase I Combination Trials: Recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee  
Channing J. Paller, Penelope A. Bradbury, S. Percy Ivy, Lesley Seymour, Patricia M. LoRusso, Laurence Baker, Larry Rubinstein, Erich Huang, Deborah Collyar, Susan Groshen, Steven Reeves, Lee M. Ellis, Daniel J. Sargent, Gary L. Rosner, Michael L. LeBlanc, and Mark J. Ratain

**4218** Phase II Study of Single-Agent Orteronel (TAK-700) in Patients with Nonmetastatic Castration-Resistant Prostate Cancer and Rising Prostate-Specific Antigen  
Maha Hussain, Paul G. Corn, M. Dror Michaelson, Hans J. Hammers, Joshi J. Alumkal, Charles J. Ryan, Justine Y. Bruce, Susan Moran, Shih-Yuan Lee, H. Mark Lin, and Daniel J. George for the Prostate Cancer Clinical Trials Consortium, a program of the Department of Defense Prostate Cancer Research Program and the Prostate Cancer Foundation

**4228** Treatment with Chemotherapy and Dendritic Cells Pulsed with Multiple Wilms' Tumor 1 (WT1)–Specific MHC Class I/II–Restricted Epitopes for Pancreatic Cancer  
Shigeo Koido, Sadamu Homma, Masato Okamoto, Kazuki Takakura, Masako Morii, Shinji Yoshizaki, Shintaro Tsukinaga, Shunichi Odahara, Seita Koyama, Hiroo Imazu, Kan Uchiyama, Mikio Kajihara, Hiroshi Arakawa, Takeyuki Misawa, Yoichi Toyama, Satoru Yanagisawa, Masahiro Ikegami, Shin Kan, Kazumi Hayashi, Hide Komita, Yuko Kamata, Masaki Ito, Takefumi Ishidao, Sei-ichi Yusa, Shigetaka Shimodaira, Jianlin Gong, Haruo Sugiyama, Toshifumi Ohkusa, and Hisao Tajiri

**4240** Randomized Phase Ib/II Trial of Rilotumumab or Ganitumab with Panitumumab versus Panitumumab Alone in Patients with Wild-type KRAS Metastatic Colorectal Cancer  
Phase I Expansion and Pharmacodynamic Study of the Oral MEK Inhibitor RO4987655 (CH4987655) in Selected Patients with Advanced Cancer with RAS–RAF Mutations

Multifactorial T-cell Hypofunction That Is Reversible Can Limit the Efficacy of Chimeric Antigen Receptor–Transduced Human T cells in Solid Tumors

Functional Kinomics Identifies Candidate Therapeutic Targets in Head and Neck Cancer
Russell Moser, Chang Xu, Michael Kao, James Annis, Luisa Angelica Lema, Christopher M. Schaupp, Kay E. Gurley, In Sock Jang, Aseil Biktasova, Wendell G. Yarbrough, Adam A. Margolin, Carla Grandori, Christopher J. Kemp, and Eduardo Méndez
See related commentary, p. 4173

Intraperitoneal Oxidative Stress in Rabbits with Papillomavirus-Associated Head and Neck Cancer Induces Tumoricidal Immune Response That Is Adoptively Transferable
Annette Rossmann, Robert Mandic, Jochen Heinis, Helmut Hoffken, Oliver Kissner, Ralf Kinscherf, Eberhard Weihe, and Michael Bette

Targeting Cancer Cells via the Reactive Oxygen Species-Mediated Unfolded Protein Response with a Novel Synthetic Polyphenol Conjugate
Soon Young Shin, Jong Min Lee, Mi So Lee, Dongsoo Koh, Hyeryoung Jung, Yoongho Lim, and Young Han Lee

Acquired Resistance to Endocrine Treatments Is Associated with Tumor-Specific Molecular Changes in Patient-Derived Luminal Breast Cancer Xenografts
Paul Cotto, Ivan Bieche, Franck Assayag, Rania El Botty, Sophie Chataye-Joubert, Aurélie Thuleau, Thomas Bagarre, Benoit Albaud, Audrey Rapihat, David Gentien, Pierre de la Grange, Vonick Sibut, Sophie Vacher, Rana Hatem, Jean-Luc Servely, Jean-Jacques Fontaine, Didier Decaudin, Jean-Yves Pierga, Sergio Roman-Roman, and Elisabetta Marangoni

Kidney Cancer Is Characterized by Aberrant Methylation of Tissue-Specific Enhancers That Are Prognostic for Overall Survival
Caroline Y. Hu, Davoud Mohtat, Yiting Yu, Yi-An Ko, Niraj Shenoy, Sanchari Bhattacharya, Maria C. Izquierdo, Ae Seo Deok Park, Orsolya Giricz, Nishanth Vallumsetla, Krishna Gundabolu, Kristin Ware, Tushar D. Bhaagat, Masako Suzuki, James Pullman, X. Shirley Liu, John M. Greally, Katalin Susztak, and Amit Verma

Molecular Testing for Lymph Node Metastases as a Determinant of Colon Cancer Recurrence: Results from a Retrospective Multicenter Study
A Novel KLF4/LDHA Signaling Pathway Regulates Aerobic Glycolysis in and Progression of Pancreatic Cancer
Min Shi, Jiujie Cui, Jiawei Du, Daoyan Wei, Zhihui Jia, Jun Zhang, Zhenggang Zhu, Yong Gao, and Keping Xie

Preoperative GNAS and KRAS Testing in the Diagnosis of Pancreatic Mucinous Cysts

Circulating CD4+ T Cells That Produce IL4 or IL17 When Stimulated by Melan-A but Not by NY-ESO-1 Have Negative Impacts on Survival of Patients with Stage IV Melanoma

PBX1 Is a Favorable Prognostic Biomarker as It Modulates 13-cis Retinoic Acid–Mediated Differentiation in Neuroblastoma
Nilay Shah, Jianjun Wang, Julia Selich-Anderson, Garrett Graham, Hasan Siddiqui, Xin Li, Javed Khan, and Jeffrey Toretsky

Correction: Interleukin-7 Mediates Selective Expansion of Tumor-Redirected Cytotoxic T Lymphocytes (CTLs) without Enhancement of Regulatory T-Cell Inhibition

Correction: A Phase I Trial of LY2510924, a CXCR4 Peptide Antagonist, in Patients with Advanced Cancer

Correction: Bim Polymorphisms: Influence on Function and Response to Treatment in Children with Acute Lymphoblastic Leukemia

Integrative analysis of clear cell renal cell carcinoma shows predominant hypermethylation. A circos plot shows alterations in DNA methylation (hypermethylation in blue, outer ring), copy number variations (amplifications in red and deletions in green, middle ring), and expression (underexpressed in green, overexpressed in orange, innermost ring) in renal cell carcinoma when compared. For details, see the article by Hu and colleagues on page 4349 of this issue.